Oncolytics Biotech Coverage Initiated at Needham & Company (ONCY)
Equities researchers at Needham & Company initiated coverage on shares of Oncolytics Biotech (NASDAQ:ONCY) in a research report issued on Thursday, Stock Ratings Network reports. The firm set a “buy” rating and a $8.00 price target on the stock. Needham & Company’s target price suggests a potential upside of 189.86% from the company’s current price.
Separately, analysts at Zacks upgraded shares of Oncolytics Biotech (NASDAQ:ONCY) from a “neutral” rating to an “outperform” rating in a research note to investors on Monday, August 5th. They now have a $3.00 price target on the stock.
One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Oncolytics Biotech currently has an average rating of “Buy” and an average target price of $5.50.
Shares of Oncolytics Biotech (NASDAQ:ONCY) traded down 2.13% during mid-day trading on Thursday, hitting $2.76. The stock had a trading volume of 464,949 shares. Oncolytics Biotech has a 52-week low of $1.60 and a 52-week high of $4.93. The stock has a 50-day moving average of $2.7 and a 200-day moving average of $2.84. The company’s market cap is $233.9 million.
Oncolytics Biotech (NASDAQ:ONCY) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.06) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.13) by $0.07. Analysts expect that Oncolytics Biotech will post $-0.25 EPS for the current fiscal year.
Oncolytics Biotech Inc (NASDAQ:ONCY) is a development-stage company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.